GLP-1 Reseptör Agonistleri

Vazirnia A, Smart DR, Mohseni Y, Amron DM. Lipedema diagnosis, clinical manifestations, and therapeutics: a systematic review. Int J Dermatol. 2026.

Herbst KL, Kahn LA, Iker E, Ehrlich C, et al. Standard of care for lipedema in the United States. Phlebology.2021;36(10):779-796.

Mohseni Y, Vazirnia A, Minokadeh A, Amron DM, Coleman WP III. Targeting Inflammation and Fibrosis in Lipedema: The Potential Role of Glucagon-like Peptide-1 Receptor Agonist Therapies. Dermatologic Surgery.2026;52(6S):72-75.

Kruppa P, Georgiou I, Biermann N, Prantl L, Klein-Weigel P, Ghods M. Lipedema-Pathogenesis, Diagnosis, and Treatment Options. Dtsch Arztebl Int. 2020 Jun 1;117(22-23):396-403.

Zheng Z, Zong Y, Ma Y, et al. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):234.

Cifarelli, Vincenza, et al. "Adipose Tissue Biology and Effect of Weight Loss in Women With Lipedema." Diabetes 74.3 (2025).

Ábel T, Csobod Csajbókné É. Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control. International Journal of Molecular Sciences. 2026; 27(3):1186.

Berto-Junior C, Blanco GGR, Marcello LV, et al. Effects of Semaglutide on Lipid Metabolism and C-Reactive Protein in Obesity: A Review of STEP Trials. Drugs and Drug Candidates. 2026; 5(2):35.

Viana DPDC, Câmara LC. Metabolic Therapy for Lipedema: Can Tirzepatide Overcome the Treatment Gap? Journal of Pharmaceutical Research International. 2025;37(3):21-28.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1): Body Composition and Subcutaneous Fat Changes. N Engl J Med. 2022;387(3):205-217.

Liu, Q.K. Mechanisms of Action and Therapeutic Applications of GLP-1 and Dual GIP/GLP-1 Receptor Agonists. Front. Endocrinol. 2024, 15, 1431292.

Builes-Montaño CE, Suarez-Rodriguez AF, Alzate-Vinasco MA. Dose–Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis. Diabetes Ther. 2026.

Rosenstock, J.; Wysham, C.; Frías, J.P.; et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial. Lancet 2021, 398, 143–155.

Viana DPdC, Invitti AL, Schor E. Tirzepatide as a Potential Disease-Modifying Therapy in Lipedema: A Narrative Review on Bridging Metabolism, Inflammation, and Fibrosis. International Journal of Molecular Sciences. 2025; 26(21):10741.

Patton L, Reverdito V, Bellucci A, Bortolon M, et al. A case series on the efficacy of the pharmacological treatment of lipedema: the Italian experience with exenatide. Clin Pract 2025; 15:128.